» Articles » PMID: 25166041

Bone Markers and Osteoporosis Therapy

Overview
Specialty Endocrinology
Date 2014 Aug 29
PMID 25166041
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Several factors are involved in determining bone quality including bone density, bone turnover, the extent of trabecular bone connectivity, cortical porosity and geometry. Metabolically active and in a continuous process of remodeling, approximately 20% of bone tissue is renewed annually. Bone turn over markers (BTM) are frequently used in clinical trials and to provide valid information about the effectiveness of osteoporosis treatment, reflecting the state of bone metabolism and its response to treatment, although they are not useful alone to estimate bone loss. In this review the behavior of BTM from different clinical trials or different osteoporotic drugs will be addressed.

Citing Articles

Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.

Zhang Q, Gao W, Xu X, Cui R, Su B Osteoporos Int. 2025; .

PMID: 40038109 DOI: 10.1007/s00198-025-07448-7.


Vitamin D Status Is Negatively Related to Insulin Resistance and Bone Turnover in Chinese Non-Osteoporosis Patients With Type 2 Diabetes: A Retrospective Cross-Section Research.

Zhang J, Li Y, Lai D, Lu D, Lan Z, Kang J Front Public Health. 2022; 9:727132.

PMID: 35223754 PMC: 8873521. DOI: 10.3389/fpubh.2021.727132.


Effect of local application of biphosphonates on improving peri-implant osseointegration in type-2 diabetic osteoporosis.

Ding X, Yang L, Hu Y, Yu J, Tang Y, Luo D Am J Transl Res. 2019; 11(9):5417-5437.

PMID: 31632520 PMC: 6789268.


Up-regulation of microRNA-340 promotes osteosarcoma cell apoptosis while suppressing proliferation, migration, and invasion by inactivating the CTNNB1-mediated Notch signaling pathway.

Pan B, Wu L, Pan L, Yang Y, Li H, Dai Y Biosci Rep. 2018; 38(4).

PMID: 29769415 PMC: 6117618. DOI: 10.1042/BSR20171615.


Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

Festuccia F, Jafari M, Moioli A, Fofi C, Barberi S, Amendola S J Nephrol. 2016; 30(2):271-279.

PMID: 27394428 DOI: 10.1007/s40620-016-0334-1.